Hongbo Deng

Hongbo Deng has extensive experience in the pharmaceutical industry. Hongbo began their career in 2003 as a Scientist at Alantos Pharmaceuticals, which was later acquired by Amgen, Inc. In 2007, they joined Vertex Pharmaceuticals as a Senior Research Scientist where they worked on cMet Kinase inhibitors for hepatic cellular carcinoma (HCC), as well as DNA-PK inhibitors, influenza virus RNA polymerase PB2 inhibitors, muscarinic antagonists for pain, and AATD. In 2021, they joined Ensem Therapeutics as the Director of Medicinal Chemistry.

Hongbo Deng began their educational journey in 1987 when they attended Dalian University of Technology, where they earned a Bachelor of Science degree in Organic Chemistry in 1991. Hongbo then went on to the University of California, Santa Cruz, where they completed their Doctor of Philosophy (Ph.D.) in 2001. Afterward, they worked as a Postdoctoral fellow at Boston College from 2001 to 2003.